“Overall, we're seeing that the growth here in Hugo is contributing to the growth we've seen now in the Surgical business across the last couple of quarters, and it will become a more and more important part of our business as we move forward.”

In context

“eing that progress continue here as we've moved into this quarter. More broadly, we've seen good progress really and continue to be encouraged about the progress we're making across the program. We're now selling in five regions around the globe. Greater China, Asia, Western Europe, LatAm, North America and Canada. And increased our installations again here in this quarter. I think importantly, we've also seen an increasing flow or a steady flow of increasing indication approvals. So we received the general surgery indication in Japan. And so now we have a full suite of approvals across general surgery, gynecology and urology in both Japan and Western Europe, which are two of the largest markets around the globe. Of course, US is the largest and that's one we remain incredibly focused on. Overall, we're seeing that the growth here in Hugo is contributing to the growth we've seen now in the Surgical business across the last couple of quarters, and it will become a more and more important part of our business as we move forward. Geoff Martha: Yeah, really look -- excited about the setup we have for our business. It's a very large business for us that where the supply capacity has been an issue, that's in a much better spot. The robots out there might just walk through kind of indication expansion and geographic expansion and update on the US trial. And I like the set up and the competitive dynamics going forward over the next couple of years. We got two major competitors, one with robot, one without. And we're feeling pretty good about where we are with Surgery. Ryan Weispfenning: Thanks, Joanne. I still see a number of people in the queue, and I apologize that we won't be able to get to all of you today, given timing. We've got time for one more question, please, Brad. Brad Welnick: Our final question comes from”